Abraxis BioScience, Inc. (ABII)
$34.43
1.28 (+3.86%)
| CAPS Rating |
|
|---|---|
| Open | $33.65 |
| Previous Close | $33.15 |
| Daily Range | $32.83 - $34.92 |
| 52-Week Range | $24.52 - $74.50 |
| Market Cap | $1.38B |
| P/E Ratio | 217.21 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 33,204 |
| Average Daily Volume | 52,000 |
ABII
VS S&P 500 (SPY)
How do you think ABII will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ABII Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ABII News and Commentary
- 5 Stocks Losing Top Investor Support – The Motley Fool
- Today's 5-Star Movers – The Motley Fool
- Fearful Stocks for Greedy Investors – The Motley Fool
- A One-Hit Wonder Goes for No. 2 – The Motley Fool
- Abraxis Fires AstraZeneca, Gets Fired Up – The Motley Fool
- Genentech Exhales – The Motley Fool
- Bristol Rolls Snake Eyes in Europe – The Motley Fool
- The Little Chemotherapy That Could – The Motley Fool
- 3 Stocks Hitting High Notes – The Motley Fool
- Now That's the Way to Spin Off a Company – The Motley Fool
Related News and Articles
- This Top Stock Is a Winner – The Motley Fool
- Amylin Scores a Hat Trick – The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- This Just In: Upgrades and Downgrades – The Motley Fool
- Finally Convinced? Benlysta Works! – The Motley Fool
- Winners and Losers of the House Health-Care Reform Bill – The Motley Fool
- Earnings? Yawn. Trial Data? Moving! – The Motley Fool
- Small and Volatile, but Not for Long – The Motley Fool
RSS Headlines
Fool UK
